Hyperlipidemia Market to Register Stunning Growth During the Forecast Period | Amgen Inc., AstraZeneca PLC, Daiichi Sankyo Company Limited, Eli Lilly and Company, Esperion Therapeutics Inc., GSK

 Breaking News
  • No posts were found

Hyperlipidemia Market to Register Stunning Growth During the Forecast Period | Amgen Inc., AstraZeneca PLC, Daiichi Sankyo Company Limited, Eli Lilly and Company, Esperion Therapeutics Inc., GSK

June 13
07:44 2024
Hyperlipidemia Market to Register Stunning Growth During the Forecast Period | Amgen Inc., AstraZeneca PLC, Daiichi Sankyo Company Limited, Eli Lilly and Company, Esperion Therapeutics Inc., GSK
Hyperlipidemia Market
As per DelveInsight, the Hyperlipidemia Market is anticipated to grow in the coming years owing to the increase in the prevalence of Hyperlipidemia and the expected launch of emerging therapies in the market.

Companies across the globe are diligently working toward the development of novel treatment therapies, with a considerable amount of success over the years. Key players, such as AstraZeneca, Silence Therapeutics plc., and others, are developing drugs to treat Hyperlipidemia. The pipeline for Hyperlipidemia consists of some key assets, i.e., AZD8233, SLN360, and others, which, after a successful launch, are anticipated to transform the treatment scenario.

DelveInsight’s “Hyperlipidemia Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Hyperlipidemia market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The Hyperlipidemia market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Hyperlipidemia Overview

Hyperlipidemia, also known as dyslipidemia or high cholesterol, is a condition characterized by elevated levels of lipids (fats) in the blood. The liver naturally produces cholesterol to aid in digestion and hormone production. However, additional cholesterol from dietary sources, particularly meat and dairy products, can lead to an excess in the body. Since the liver produces all the cholesterol the body needs, dietary cholesterol is considered surplus.

Excessive cholesterol (200 to 239 mg/dL is borderline high, and 240 mg/dL is high) can be detrimental to health. It can accumulate as plaques in the arteries, obstructing blood flow and potentially damaging organs. Low-density lipoprotein (LDL), often termed “bad cholesterol,” is particularly harmful as it leads to hardened cholesterol deposits within blood vessels. This buildup restricts blood flow, increasing the risk of stroke or heart attack.

Hyperlipidemia is categorized into two main types: primary (familial) and secondary (acquired).

Primary Hyperlipidemia: Stemming from genetic disorders inherited at birth.

Secondary Hyperlipidemia: Resulting from other underlying conditions or factors such as an unhealthy diet, certain medications (e.g., amiodarone, glucocorticoids), hypothyroidism, uncontrolled diabetes, and poor lifestyle habits.

Hyperlipidemia often lacks specific symptoms. However, plaque buildup can significantly reduce or block blood flow to the heart or brain, leading to symptoms such as chest pain during exertion, jaw pain, flushing, nausea, and shortness of breath. This can ultimately cause severe cardiovascular events like heart attacks or strokes.

Key facts from the Hyperlipidemia Market Report:

  • According to the research study by Hill et al. (2022), There are over 3 million adults throughout the United States and Europe that currently have a diagnosis of hyperlipidemia, and that number continues to rise at a drastic pace. The degree of Hyperlipidemia is highest in patients with premature coronary artery disease (CAD), defined as CAD arising in males before age 55 to 60 years and females before age 65 years.

  • The Hyperlipidemia epidemiology covered in the report provides historical as well as forecasted epidemiology segmented as Total Prevalent Cases of Hyperlipidemia, Total Diagnosed Prevalent Cases of Hyperlipidemia, Gender-specific Diagnosed Prevalent Cases of Hyperlipidemia, Etiology-specific Diagnosed Prevalent Cases of Hyperlipidemia, and Treated Cases of Hyperlipidemia in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2019 to 2032.

Hyperlipidemia Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current and forecasted Hyperlipidemia market size by analyzing the impact of current and emerging pipeline therapies. It also thoroughly assesses the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete detail of the Hyperlipidemia market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Learn How the Hyperlipidemia Market Will Evolve and Grow by 2032 @ https://www.delveinsight.com/sample-request/hyperlipidemia-market

Hyperlipidemia Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and views of key opinion leaders. 

The Report Covers the Hyperlipidemia Epidemiology, Segmented as –

  • Total Prevalent Cases of Hyperlipidemia in the 7MM [2019–2032]

  • Etiology-specific Prevalent Cases of Hyperlipidemia in the 7MM [2019–2032]

  • Diagnosed and Treatable Cases of Hyperlipidemia in the 7MM [2019–2032]

  • Gender-specific Prevalent Cases of Hyperlipidemia in the 7MM [2019–2032]

  • Hyperlipidemia Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Hyperlipidemia market or expected to be launched during the study period. The analysis covers the Hyperlipidemia market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Hyperlipidemia pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Key Companies in the Hyperlipidemia Therapeutics Market Include: Amgen Inc., AstraZeneca PLC, Daiichi Sankyo Company Limited, Eli Lilly and Company, Esperion Therapeutics Inc., GlaxoSmithKline Pharmaceuticals Limited (GlaxoSmithKline Plc), Immuron Limited, Ionis Pharmaceuticals Inc., Merck & Co. Inc., Pfizer Inc. and Sanofi S.A., and others.

Hyperlipidemia Therapies Covered in the Report Include:

  • AZD8233: AstraZeneca

  • SLN360: Silence Therapeutics/Medpace

  • Leqvio (inclisiran): Novartis

  • Nexletol (bempedoic acid): Esperion

The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @ https://www.delveinsight.com/sample-request/hyperlipidemia-market

Table of Contents

1. Key Insights

2. Executive Summary 

3. Hyperlipidemia Competitive Intelligence Analysis

4. Hyperlipidemia Market Overview at a Glance

5. Hyperlipidemia Disease Background and Overview

6. Hyperlipidemia Patient Journey

7. Hyperlipidemia Epidemiology and Patient Population (In the US, EU5, and Japan)

8. Hyperlipidemia Treatment Algorithm, Current Treatment, and Medical Practices

9. Hyperlipidemia Unmet Needs

10. Key Endpoints of Hyperlipidemia Treatment

11. Hyperlipidemia Marketed Products

12. Hyperlipidemia Emerging Drugs and Latest Therapeutic Advances

13. Hyperlipidemia Seven Major Market Analysis

14. Attribute Analysis

15. Hyperlipidemia Market Outlook (In US, EU5, and Japan)

16. Hyperlipidemia Access and Reimbursement Overview

17. KOL Views on the Hyperlipidemia Market

18. Hyperlipidemia Market Drivers

19. Hyperlipidemia Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/